Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon May 03, 2023 6:42pm
356 Views
Post# 35428767

New trial update on FDA/Multiple melanoma

New trial update on FDA/Multiple melanomaFew are even aware onc was involved with BMS with a multiple melanoma trial.
They just added National cancer INstitute & another agency as colaborators.
Also note in the consent form, It clearly states both ONC & BMS are splitting the cost of the trial.


https://www.clinicaltrials.gov/ct2/history/NCT03605719?A=9&B=10&C=merged#StudyPageTop


Perhaps this will be the news/pre-Friday Q1 update?
Could be a little soon, depends what they discovered.

The Winship MM study has been off the investor update page for months.
Adding the N.C.I. , could mean nothing. The again, why advance the involvment with bad news.

<< Previous
Bullboard Posts
Next >>